A multiple ascending dose study of CSL112, an infused formulation of ApoA-I

Journal of Clinical Pharmacology

Volumn 54, Issue 3, 2014, Pages 301-310

  Easton, Rachael ^a   Gille, Andreas ^b   D'Andrea, Denise ^a   Davis, Roslyn ^b   Wright, Samuel D ^a   Shear, Charles ^a  

^a CSL Behring LLC   (United States)

^b CSL LIMITED   (Australia)

Author keywords

acute coronary syndrome; apolipoprotein A I; CSL112; pharmacokinetics; reconstituted HDL

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARDIOVASCULAR AGENT; CSL112; PARACETAMOL; PHOSPHATIDYLCHOLINE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD PRESSURE; BODY TEMPERATURE; BODY WEIGHT; BREATHING RATE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSMENORRHEA; ELECTROCARDIOGRAPHY; FEMALE; HEADACHE; HEMATOMA; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFUSION SITE HEMATOMA; INFUSION SITE PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; MEDIASTINUM DISEASE; NORMAL HUMAN; OROPHARYNX PAIN; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PLASMA VOLUME; PRESYNCOPE; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; RESPIRATORY TRACT DISEASE; SIDE EFFECT; THORAX DISEASE; THROMBOCYTE FUNCTION; TYMPANIC TEMPERATURE; VESSEL PUNCTURE SITE HEMATOMA; VESSEL PUNCTURE SITE REACTION; VESSEL PUNCTURE SITE SWELLING;

ACUTE CORONARY SYNDROME; APOLIPOPROTEIN A-I; CSL112; PHARMACOKINETICS; RECONSTITUTED HDL;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; APOLIPOPROTEIN A-I; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LIPOPROTEINS, HDL; MALE; PHOSPHATIDYLCHOLINES; PLATELET AGGREGATION; YOUNG ADULT;

EID: 84898643356     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.194     Document Type: Article

References (26)

1. World Health Organization. What are cardiovascular diseases (CVDs)? In:, Mendis S, Puska P, Norrving B, eds. Global Atlas on Cardiovascular Disease Prevention and Control. Geneva: WHO; 2011, p. 2.
2. World Health Organization. World Health Statistics 2012, Part II Highlighted Topics. Available at: http://www.who.int/gho/publications/world- health-statistics/en/ Accessed May 2013.
3. Mahoney EM, Wang K, Cohen DJ, et al. One-year costs in patients with a history of or at risk for atherothrombosis in the United States. Circ Cardiovasc Qual Outcomes. 2008; 1: 38-45.
4. Small DM., George Lyman Duff Memorial Lecture. Progression and regression of atherosclerotic lesions. Insights from lipid physical biochemistry. Arteriosclerosis. 1988; 8: 103-129. (Pubitemid 18090919)
5. Cornel JH, Becker RC, Goodman SG, et al. Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2012; 164: 334-342.
6. Falk E, Shah PK, Fuster V., Coronary plaque disruption. Circulation. 1995; 92: 657-671.
7. Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011; 364: 226-235.
8. Fonarow GC., In-hospital initiation of statin therapy in acute coronary syndromes. Maximizing the early and long-term benefits. Chest. 2005; 128: 3641-3651. (Pubitemid 41698706)
9. Briel M, Schwartz GC, Thompson PL, et al. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes. A meta-analysis of randomized controlled trials. JAMA. 2006; 295: 2046-2056. (Pubitemid 44794006)
10. Rosenson RS, Brewer HB, Davidson WS, et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 2012; 125: 1905-1919.
11. Feig JE, Rong JX, Shamir R, et al. HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells. Proc Natl Acad Sci USA. 2011; 108: 7166-7171.
12. Remaley AT, Amar M, Sviridov D., HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications. Expert Review Cardiovasc Ther. 2008; 6: 1203-1215.
13. Tardif JC, Heinonen T, Noble S., High-density lipoprotein/apolipoprotein A-I infusion therapy. Curr Atheroscler Rep. 2009; 11: 58-63.
14. Tardif JC., Emerging high-density lipoprotein infusion therapies: fulfilling the promise of epidemiology ? J Clin Lipidol. 2010; 4: 399-404.
15. Shaw JA, Bobik A, Murphy A, et al. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circulation Res. 2008; 103: 1084-1091.
16. Diditchenko S, Gille A, Pragst I, et al. A novel formulation of a reconstituted HDL (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux. Arterioscler Thromb Vasc Biol. Published online before print: July 18, 2013; 33: 2202-2211.
17. Puig O, Yuan J, Stepaniants S, et al. A gene expression signature that classifies human atherosclerotic plaque by relative inflammation status. Circ Cardiovasc Genet. 2011; 4: 595-604.
18. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant apoA-I milano on coronary atherosclerosis in patients with acute coronary syndromes. A randomized controlled trial. JAMA. 2003; 290: 2292-2300. (Pubitemid 37430562)
19. Tardif JC, Gregoire J, L'Allier PL, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA. 2007; 297: 1675-1682. (Pubitemid 46631626)
20. US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 May 28, 2009. Available at: http://www.acrin.org/Portals/0/Administration/Regulatory/CTCAE-4. 02-2009-09-15-QuickReference-5×7.pdf Accessed December 17, 2012.
21. Maccubbin D, Bays HE, Olsson AG, et al. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract. 2008; 62: 1959-1970.
22. Tawakol A, Mani V, Niesor EJ., et al. Increased cholesterol efflux is associated with reductions in arterial wall area and inflammation as assessed by MR and FDG-PET imaging in humans: analysis of the dal-PLAQUE study. Abstract #427. Presented at Eur Soc Cardiol August 26, 2012, Munich, Germany.
23. Nicholls SJ, Gordon A, Johansson J, et al. Efficacy and safety of a novel oral inducer of apolipoprotein A-I synthesis in statin-treated patients with stable coronary artery disease. J Am Coll Cardiol. 2011; 57: 1111-1119.
24. Nicholls SJ, Gordon A, Johannson J, et al. ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies. Cardiovasc Drugs Ther. 2012; 26: 181-187.
25. Waksman R, Torguson R, Kent KM, et al. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol. 2010; 55: 2727-2735.
26. Fidge N, Nestel P, Ishikawa T, Reardon M, Billington T., Turnover of apoproteins A-I and A-II of high density lipoprotein and the relationship to other lipoproteins in normal and hyperlipidemic individuals. Metabolism. 1980; 29: 643-653. (Pubitemid 10076713)